“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Kick off 5-city medical symposium for Indian urologists in July 2018
Mumbai, June 29, 2018: Pharma major Lupin and the European Association of Urology (EAU) today announced a collaboration to further the cause of Urology in India. With this collaboration, Lupin brings European Association of Urology’s biggest event and experts to India for the very first time. The first activity as part of this collaboration will be a medical symposium for the Indian urology community scheduled to be held in July across five cities. By bringing the best of Annual EAU Congress, this program will provide Indian Urology practitioners an opportunity to get accustomed with the latest advancements made at a global level and to apply these global best practices for patients in India.
The event to be held under the banner of Masterclass, 'Best of EAU18’ is conceptualised as an educational initiative by Lupin’s Maxter division comprising medical products related to Urology. This is the first time such a program will be conducted in India, and will see a select group of world-renowned urologists in attendance to discuss clinical practices and key research developments in the field. The speakers’ list consists of Prof. Christopher Chapple, a specialist in functional Urology, whose expertise lies in functional, female and reconstructive Urology, including Benign Prostatic Hyperplasia (BPH) and Overactive bladder (OAB) syndromes; Prof. Maurizio Brausi and Prof. Arnulf Stenzl, whose specialities are in Onco-urology; and Prof. Selcuk Silay, an expert in Paediatric Urology, Andrology, and Endourology.
Commenting on the development, Mr. Rajeev Sibal, President India Business at Lupin, said, "India has seen an increasing prevalence of urological ailments possibly due to an increase in expected lifespan. Urological ailments, besides the inherent morbidity, also severely impact the day-to-day quality of life, including social and personal aspects coupled with significant economic burden. The urological ailments have increasing incidence with age and, may also be driven by sedentary lifestyle. Due to the necessity for constant knowledge upgradation of the medical professionals, there is a regular and compelling need to not only get the recent developments but get it straight from the experts. With that objective in mind, Lupin, for the first time ever in the Indian Pharma Industry, has collaborated with EAU (European Association of Urology) to bring the 'Best of EAU18’ conference to the Indian Urologists with the ultimate aim of improving the healthcare for the patients. In keeping with the academic focus, we at Lupin are driven to continue such initiatives not only in the field of Urology but also other important specialties."
"The Annual Congress of the European Association of Urology is one of the biggest and most important scientific meetings in the field of Urology, attracting around 15,000 healthcare professionals to major European cities every year", says Prof. Christopher Chapple, Secretary General of the EAU. "Our mission is to raise the level of urological care throughout Europe and beyond by encouraging urological research and broadcasting these results. With this collaboration, we bring India the best of the last Congress in Copenhagen and we look forward to sharing experiences in the various Indian cities."
Lupin’s Masterclass 'Best of EAU18’ series will begin from 14th to 21st July in five cities across the country – New Delhi, Kolkata, Hyderabad, Bangalore and Mumbai.
About the European Association of Urology (EAU)
The European Association of Urology is a non-profit organisation which supports medical professionals working in the field of urology through many of its scientific, professional, educational and awareness-building initiatives. The overarching mission is to raise the level of urological care in Europe, and for many years this has been done through educational and scientific programmes aimed at urologists. Today the EAU represents more than 16,000 medical professionals working in Europe and beyond its borders.
The Annual Congress of the European Association of Urology is the largest and most important urology congress in Europe, with up to 14,000 participants. For more information see www.uroweb.org
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 12th and 8th largest generics pharmaceutical company by market capitalization (31st March 2018, Bloomberg) and revenues (31st Mar 2018, Bloomberg LTM) respectively. The Company is the 4th largest pharmaceutical player in the US by prescriptions (IQVIA MAT March 2018); 3rd largest Indian pharmaceutical company by global revenues (31st Mar 2018, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT March 2018).
For the financial year ended 31st March, 2018, Lupin’s Consolidated sales and Net profits were at Rs. 155,598 million (USD 2.41 billion) and Rs. 2,513 million (USD 39 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.
For further information or queries, please contact –
VP – Corporate Communications
Ph: +91-22-66402531 / 8291013225
Head – Investor Relations
*Safe Harbor Statement